Clinical evaluations revealedits effective binding in MSA patients in regions associated with α-synpathology, although it did not bind in PD patients.11 However, its off-target binding to monoamine oxidase-B(MAO-B), as indicated by preblocking experiments with selegiline,highlights a limitation. This evidence concerns the gene MAOB and Parkinson disease.